Day: May 20, 2024

FORM 8.5 (EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)        Name of exempt principal trader: Investec Bank plc(b)        Name of offeror/offeree in relation to whose relevant securities this form relates:         Use a separate form for each offeror/offeree Alpha Financial Markets Consulting plc(c)        Name of the party to the offer with which exempt principal trader is connected: Investec is Joint Broker to Alpha Financial Markets Consulting plc(d)        Date dealing undertaken:17th May 2024(e)        In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to this offer?         If...

Hepsor U34 SIA, a subsidiary of Hepsor AS Group, and construction company Mitt&Perlebach signed a contract on May 17, 2024, for the construction of a development project called StokOfiss 34 in Riga at Ulbrokas 34. The construction contract is approximately 9.6 million euros, plus value-added tax. The development will consist of a commercial building with office, commercial, and warehouse space totaling approximately 8,740 square meters. Completion is planned for the third quarter of 2025. StokOfiss U34 is designed with Hepsor’s green mindset in mind, and the building has been issued an energy class A and BREEAM sustainability certificate at the “Very good” level. “StokOfiss U34 brings high-quality and modern business space to the Riga market, allowing clients to consolidate office, commercial, and warehouse...

ATLANTA, May 19, 2024 (GLOBE NEWSWIRE) — Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company” or “Virios Therapeutics”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“FM”) and Long-COVID (“LC”), today announced the pricing of its previously announced public offering of 8,500,000 shares of its common stock at a public offering price of $0.20 per share. Gross proceeds from the offering are expected to be approximately $1.7 million before deducting placement agent fees and estimated offering expenses. The offering is expected to close on May 22, 2024, subject to customary closing conditions. Virios Therapeutics intends to use the net proceeds of the proposed offering to commence preparatory activities for its planned IMC-2...